Cadila Healthcare gains 1% on USFDA approval for Pregabalin Capsules

December 1, 2017

A wholly owned subsidiary of Cadila Healthcare, Zydus Pharmaceuticals Inc, has recently got the tentative approval to market Pregabalin Capsules of the power 25 mg, 50 mg, 75 mg, 100 mg, 200 mg, 225 mg, and 300 mg. USFDA gave the approval.

After the approval of USFDA for Pregabalin Capsules, the company shares gained more than 1 percent intraday Friday.

A wholly owned subsidiary of Cadila Healthcare, Zydus Pharmaceuticals Inc, has recently got the tentative approval to market Pregabalin Capsules of the power 25 mg, 50 mg, 75 mg, 100 mg, 200 mg, 225 mg, and 300 mg. USFDA gave the approval.

This capsule is basically used for management of certain kinds of seizures, neuropathic pain, nerve pain and fibromyalgia.

The company has its manufacturing facility at Moraiya, Ahmedabad. It will be manufactured at the group’s formulations.

The entire group keeps hold of more than 175 approvals. Since the commencement of the filing process in FY 2003-04, the company has so far filed over 310 ANDAs.

On the BSE, Cadila Healthcare was quoting at Rs 430.55, up Rs 1.15, or 0.27 percent at 13:08 hrs.

 

 

About MCR World

I started my career as content writer at Money classic Research. I am fascinated with this job and I feel habit of reading and writing enhances your skills. I love to write technical and health blogs. However, I am engineer turned writer and pursued graduation at Rajiv Gandhi Prodyogiki Vishwavidhyalaya.
By: MCR World

Leave a Reply

Your email address will not be published. Required fields are marked *